Every human cell has the same DNA and the same genes. However, the difference between cells in different tissues and organs as well as between healthy and cancer cells is that the expression of genes is different. Expression means that proteins, which are the products of the genes, are different in type, amount or modification states and these variations are the subject of Proteomics.
The Proteomics/MS TDU is a full proteomic infrastructure for several analyses ranging from simple identifications of proteins to complex analysis involving multistage separations techniques, analysis of post translational modified proteins and quantification processes, both targeted and untargeted. This includes various platforms for protein and peptide separation, and state-of-the-art mass spectrometry for MS and LC-MS/MS experiments.
The main interest of the Unit is to develop, implement and optimize proteomic based protocols along with IFOM's groups to obtain synergistic technologies to apply in cancer research. Proteomics techniques are rapidly advancing and require considerable technical expertise and expensive equipment. For this reason the aim of the IFOM Proteomics/ Mass Spectrometry Facility is to accelerate discovery in cancer proteomics by giving researchers access to cutting edge technologies in Mass Spectrometry and Proteomics.
Angela Bachi is also Principal Investigator of the Functional Proteomics program.
See her profile